Table 1. Baseline Characteristics of the Study Population at Time of Inclusion in the Study.
| Characteristic | Control group (n = 26) | CpG 7909 group (n = 28) | P value |
| Sex | 0.24 | ||
| Male | 21 (80.8) | 26 (92.9) | |
| Female | 5 (19.2) | 2 (7.14) | |
| Race | 0.23 | ||
| White | 24 (92.3) | 28 (100) | |
| Other | 2 (7.69) | 0 (0.00) | |
| Age, median years (IQR) | 48.9 (44.5–60.6) | 49.5 (44.5–61.2) | 0.58 |
| Median BMI (IQR) | 23.2 (21.9–24.8) | 24.0 (22.0–25.3) | 0.51 |
| History of AIDS-defining event | 7 (26.9) | 9 (32.1) | 0.77 |
| CD4+ cell count, median cells/ µL (IQR) | 617 (519–854) | 758 (490–868) | 0.80 |
| Nadir CD4+ cell count, median cells/ µL (IQR) | 215 768–260) | 175 (50–243) | 0.35 |
| HIV RNA level, median log10 copies/mL | 1.60 | 1.60 | 0.98 |
| Duration of HAART, median years (IQR) | 6.63 (2.91–10.8) | 9.29 (6.74–10.7) | 0.28 |
| Quantifiable HIV DNA at 0 months (before 1st immunization) | 22 (84.6) | 21 (75.0) | 0.51 |
| Quantifiable HIV DNA at 3 months (before 2nd immuization) | 24 (92.3) | 23 (82.1) | 0.42 |
| Quantifiable HIV DNA at 9 months (before 3rd immunization) | 21 (80.8) | 22 (78.6) | 1.00 |
Note: Data are no. (%) of patients, unless otherwise is indicated. BMI, body mass index; PBMCs, IQR, interquartile range.